CYP cynata therapeutics limited

CYP Price Target post MSB FDA approval., page-9

  1. 1,665 Posts.
    lightbulb Created with Sketch. 340
    Hard to justify the 50 x MC of MSB compared to CYP. If the GvHD phase 2 trial continues to demonstrate outstanding efficacy and safety, it's safe to assume it will quickly replace ruxolitinib as SoC. Ruxo has many applications, with GvHD accounting for 17% of total income. That's circa $500M USD per annum. Frankly, the potential pipeline of indications appears immense.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
17.0¢
Change
-0.005(2.86%)
Mkt cap ! $38.41M
Open High Low Value Volume
18.0¢ 18.0¢ 16.5¢ $41.91K 247.1K

Buyers (Bids)

No. Vol. Price($)
2 8275 17.0¢
 

Sellers (Offers)

Price($) Vol. No.
17.5¢ 3700 1
View Market Depth
Last trade - 16.10pm 30/07/2025 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.